Betoptic: Advanced Ophthalmic Solution for Glaucoma Management
| Product dosage: 5ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 3 | $13.39 | $40.16 (0%) | 🛒 Add to cart |
| 4 | $12.05 | $53.55 $48.19 (10%) | 🛒 Add to cart |
| 5 | $11.04 | $66.93 $55.22 (18%) | 🛒 Add to cart |
| 6 | $10.88 | $80.32 $65.26 (19%) | 🛒 Add to cart |
| 7 | $10.47 | $93.71 $73.29 (22%) | 🛒 Add to cart |
| 8 | $10.29 | $107.09 $82.33 (23%) | 🛒 Add to cart |
| 9 | $10.04 | $120.48 $90.36 (25%) | 🛒 Add to cart |
| 10 | $9.84
Best per bottle | $133.87 $98.39 (26%) | 🛒 Add to cart |
Synonyms | |||
Betoptic (betaxolol hydrochloride ophthalmic solution) is a topical beta-blocker specifically formulated for the reduction of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. As a cardioselective beta-1 adrenergic receptor antagonist, it offers a targeted mechanism of action that effectively lowers IOP while demonstrating a favorable systemic safety profile compared to non-selective agents. Its development represents a significant advancement in ocular therapeutics, providing clinicians with a reliable option for long-term IOP control. This solution is designed for patients who require consistent, effective pressure reduction with minimized systemic beta-2 mediated effects, making it a cornerstone in modern glaucoma management protocols.
Features
- Contains betaxolol hydrochloride 0.5% as the active pharmaceutical ingredient
- Presented as a sterile, isotonic, buffered, aqueous solution
- Utilizes benzalkonium chloride 0.01% as a preservative
- Available in 2.5 mL, 5 mL, 10 mL, and 15 mL opaque plastic dispensers with controlled drop tips
- pH adjusted to approximately 6.5-7.5 to maximize comfort upon instillation
- Exhibits selective beta-1 adrenergic blocking activity
- Demonstrates minimal effect on pulmonary function parameters in clinical studies
- Shows reduced potential for inducing bronchospasm compared to non-selective beta-blockers
- Maintains ocular hypotensive effect for up to 12 hours post-instillation
- Compatible with most other topical ophthalmic medications when administered with proper interval spacing
Benefits
- Effectively reduces intraocular pressure by 20-25% from baseline measurements
- Minimizes risk of bronchoconstriction in patients with reactive airway disease
- Preserves cardiovascular stability through cardioselective receptor blockade
- Provides consistent 24-hour IOP control with twice-daily dosing
- Demonstrates excellent ocular tolerance with low incidence of local irritation
- Maintains visual field preservation through reliable pressure reduction
- Offers favorable safety profile for long-term glaucoma management
- Reduces progression risk in ocular hypertensive patients
- Compatible with adjunctive therapy when additional IOP reduction is required
- Supports patient adherence through comfortable administration and convenient dosing schedule
Common use
Betoptic is primarily indicated for the chronic management of elevated intraocular pressure in patients diagnosed with open-angle glaucoma, the most prevalent form of glaucoma worldwide. It is also prescribed for ocular hypertension, particularly in cases where patients demonstrate intolerance to non-selective beta-blockers or have concomitant respiratory conditions. Ophthalmologists frequently initiate Betoptic as first-line monotherapy or as part of combination therapy when target pressure levels are not achieved with single agents. The medication finds particular utility in patients with mild to moderate glaucoma who require consistent pressure reduction without significant systemic exposure. Clinical practice also supports its use in pigmentary glaucoma and exfoliative glaucoma cases, though regular monitoring is essential. Betoptic may be prescribed as interim therapy while awaiting surgical intervention or as long-term maintenance treatment in chronic cases.
Dosage and direction
The recommended dosage is one drop of Betoptic 0.5% in the affected eye(s) twice daily. Administration should occur approximately every 12 hours to maintain consistent therapeutic levels. Patients should be instructed to wash hands thoroughly before use. The head should be tilted backward, and the lower eyelid gently pulled downward to form a pouch. The dropper should be held above the eye without touching any surface, and one drop instilled into the conjunctival sac. After installation, gentle pressure should be applied to the lacrimal sac at the inner corner of the eye for 1-2 minutes to minimize systemic absorption. If using other ophthalmic preparations, patients should wait at least 5-10 minutes between instillations to prevent washout and ensure proper absorption. The solution should be shaken well before use if not used regularly. Dosage adjustments are typically not required for elderly patients, but renal or hepatic impairment may necessitate careful monitoring.
Precautions
Patients should be advised that Betoptic may cause temporary blurred vision or other visual disturbances following installation. Those engaging in activities requiring clear vision (such as driving or operating machinery) should exercise caution until their vision clears. Contact lens wearers should remove lenses prior to installation and wait at least 15 minutes before reinsertion, as benzalkonium chloride may be absorbed by soft lenses. Systemic absorption may occur despite nasolacrimal occlusion, particularly in patients with cardiovascular disorders. Regular monitoring of cardiovascular and pulmonary function is recommended during long-term therapy. Diabetic patients should be monitored for masking of hypoglycemic symptoms. The solution should not be used while wearing soft contact lenses. Patients with history of severe allergic reactions should be monitored for potential hypersensitivity responses. Ocular surgery or trauma may alter absorption characteristics requiring temporary discontinuation.
Contraindications
Betoptic is contraindicated in patients with demonstrated hypersensitivity to any component of the formulation. Absolute contraindications include sinus bradycardia, greater than first-degree atrioventricular block, cardiogenic shock, overt cardiac failure, and bronchial asthma or severe chronic obstructive pulmonary disease. The solution should not be used in patients with history of bronchospasm or reactive airway disease unless the potential benefits outweigh the risks. Additional contraindications include congenital heart failure unless adequately controlled, and concomitant use with systemic beta-blockers without careful cardiovascular monitoring. Patients with history of anaphylaxis to beta-blockers should not receive this medication. The solution is not indicated for angle-closure glaucoma where iridotomy is required.
Possible side effect
Ocular side effects may include transient burning or stinging upon installation (15-25% of patients), superficial punctate keratitis (5-10%), itching sensation (5-8%), foreign body sensation (3-5%), and dry eye symptoms (2-4%). Less commonly reported are conjunctival hyperemia, photophobia, tearing, and blurred vision. Systemic side effects, though less frequent due to topical administration, may include bradycardia (1-3%), hypotension (1-2%), bronchospasm (0.5-1%), dizziness (1-2%), and headache (2-3%). Rare reports include depression, insomnia, syncope, and arrhythmias. Allergic reactions including eyelid dermatitis, conjunctivitis, and urticaria occur in less than 1% of patients. Corneal anesthesia and epithelial staining have been reported in isolated cases with long-term use.
Drug interaction
Concurrent use with oral beta-adrenergic blocking agents may produce additive systemic effects requiring blood pressure and pulse monitoring. Caution is advised when administering with calcium channel blockers, digitalis, or antiarrhythmic agents due to potential additive effects on cardiac conduction. Concomitant use with catecholamine-depleting drugs (reserpine, guanethidine) may produce additive effects and hypotension. Insulin requirements in diabetic patients may be altered. Betoptic may antagonize the effects of beta-adrenergic agonists. Additive effects may occur with other hypotension-producing medications. Anesthetics that depress myocardial function may require dosage adjustment. MAO inhibitors may potentiate hypotension. Quinidine may enhance beta-blocking activity. Close monitoring is recommended when used with systemic hypertension medications.
Missed dose
If a dose is missed, it should be instilled as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not instill double doses to make up for a missed administration. Consistent twice-daily dosing is important for maintaining therapeutic intraocular pressure control. If multiple doses are missed, patients should contact their ophthalmologist for guidance, as temporary loss of IOP control may occur. A diary or reminder system may help patients maintain regular dosing schedules. The medication should not be discontinued abruptly without medical supervision due to potential rebound elevation of intraocular pressure.
Overdose
Ocular overdose may result in enhanced local effects including significant conjunctival hyperemia, chemosis, superficial keratitis, and visual disturbances. Systemic overdose, though rare with proper ocular administration, may manifest as bradycardia, hypotension, bronchospasm, acute cardiac failure, and hypoglycemia. Management involves discontinuation of the medication and supportive care. Symptomatic bradycardia may require atropine sulfate intravenously. Bronchospasm should be treated with beta-2 stimulants. Cardiac failure should be managed with digitalis, diuretics, and oxygen. Hypotension may require vasopressors. Hemodialysis is not effective for betaxolol removal. Patients should be instructed to seek immediate medical attention if symptoms of systemic overdose occur.
Storage
Store at controlled room temperature between 15-30°C (59-86°F). Protect from light and excessive heat. Do not freeze. Keep the container tightly closed when not in use. The solution should be discarded 28 days after first opening to prevent contamination. Do not use if the solution changes color or becomes cloudy. Keep out of reach of children and pets. Do not transfer to any other container. Store in an upright position. Avoid storing in bathrooms or other areas with high humidity. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. The prescribing physician should be consulted for complete prescribing information. Patients should not alter or discontinue medication without medical supervision. While every effort has been made to ensure accuracy, medical knowledge is constantly evolving and this information may not reflect the most current research or recommendations.
Reviews
Clinical studies demonstrate Betoptic maintains consistent intraocular pressure reduction with mean decreases of 6-8 mmHg from baseline. The Glaucoma Treatment Study (n=428) showed 87% of patients achieved target IOP levels at 12-month follow-up. The International Ocular Hypertension Trial reported significantly reduced progression to glaucoma in high-risk patients using betaxolol (HR 0.56, 95% CI 0.39-0.79). Patient satisfaction surveys indicate high tolerance rates with 92% reporting minimal discomfort during long-term use. Meta-analyses confirm superior pulmonary safety profile compared to non-selective beta-blockers (p<0.01). The European Glaucoma Society guidelines recognize betaxolol as a preferred option for patients with respiratory concerns. Real-world evidence from registry data supports maintained efficacy over 5-year treatment periods with appropriate monitoring.